Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
400.1 USD | +1.05% | +6.24% | +30.41% |
Apr. 24 | Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Medpace Holdings, Inc., Q1 2024 Earnings Call, Apr 23, 2024 |
Business Summary
Number of employees: 5,800
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncology
31.1
%
| 468 | 32.0 % | 587 | 31.1 % | +25.50% |
Other
21.5
%
| 297 | 20.3 % | 405 | 21.5 % | +36.35% |
Metabolic
20.0
%
| 245 | 16.8 % | 377 | 20.0 % | +54.01% |
Cardiology
10.3
%
| 175 | 12.0 % | 194 | 10.3 % | +10.91% |
Antiviral and Anti-infective
8.7
%
| 118 | 8.1 % | 163 | 8.7 % | +38.36% |
Central Nervous System
8.5
%
| 158 | 10.8 % | 160 | 8.5 % | +1.34% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
98.0
%
| 1,431 | 98.0 % | 1,848 | 98.0 % | +29.17% |
International
2.0
%
| 29 | 2.0 % | 38 | 2.0 % | +29.17% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
August Troendle
CEO | Chief Executive Officer | 67 | 92-06-30 |
Kevin Brady
DFI | Director of Finance/CFO | 49 | 18-10-31 |
Jesse Geiger
PSD | President | 49 | 07-09-30 |
Brandon Ebken
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-30 |
Daniel O’Leary
CTO | Chief Tech/Sci/R&D Officer | - | - |
Reinilde Heyrman
CTO | Chief Tech/Sci/R&D Officer | 63 | 17-08-31 |
Susan Burwig
COO | Chief Operating Officer | 61 | 93-07-31 |
Stephen Ewald
CMP | Compliance Officer | 54 | 12-05-31 |
Lauren Morris
IRC | Investor Relations Contact | - | - |
Todd Meyers
SAM | Sales & Marketing | - | 13-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Davenport
BRD | Director/Board Member | 72 | 18-08-12 |
August Troendle
CEO | Chief Executive Officer | 67 | 92-06-30 |
Director/Board Member | 64 | 18-08-12 | |
Robert Kraft
BRD | Director/Board Member | 53 | 16-06-30 |
Brian Carley
BRD | Director/Board Member | 70 | 16-06-30 |
Director/Board Member | 62 | 23-01-15 | |
Ashley Keating
BRD | Director/Board Member | 42 | 19-05-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 30,983,185 | 25,355,858 ( 81.84 %) | 70,073 ( 0.2262 %) | 81.84 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
VTV THERAPEUTICS INC. 5.55% | 134,938 | 5.55% | 3,175,091 $ |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.41% | 12.24B | |
+2.43% | 42.75B | |
+47.70% | 41.61B | |
+12.06% | 41.34B | |
-8.83% | 26.59B | |
+6.65% | 25.49B | |
-22.87% | 18.12B | |
-2.05% | 11.76B | |
+9.21% | 11B | |
-15.66% | 10.07B |
- Stock Market
- Equities
- MEDP Stock
- Company Medpace Holdings, Inc.